AVCT vs. 4BB, HVO, FARN, FUM, BVXP, SCLP, POLB, REDX, ETX, and OXB
Should you be buying Avacta Group stock or one of its competitors? The main competitors of Avacta Group include 4basebio (4BB), hVIVO (HVO), Faron Pharmaceuticals Oy (FARN), Futura Medical (FUM), Bioventix (BVXP), Scancell (SCLP), Poolbeg Pharma (POLB), Redx Pharma (REDX), e-therapeutics (ETX), and Oxford Biomedica (OXB). These companies are all part of the "biotechnology" industry.
4basebio (LON:4BB) and Avacta Group (LON:AVCT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, community ranking, analyst recommendations and institutional ownership.
Avacta Group received 212 more outperform votes than 4basebio when rated by MarketBeat users.
4basebio has a net margin of 0.00% compared to 4basebio's net margin of -267.00%. Avacta Group's return on equity of -97.29% beat 4basebio's return on equity.
9.1% of 4basebio shares are owned by institutional investors. Comparatively, 8.8% of Avacta Group shares are owned by institutional investors. 62.2% of 4basebio shares are owned by company insiders. Comparatively, 29.9% of Avacta Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Avacta Group had 4 more articles in the media than 4basebio. MarketBeat recorded 4 mentions for Avacta Group and 0 mentions for 4basebio. Avacta Group's average media sentiment score of 0.00 beat 4basebio's score of -0.47 indicating that 4basebio is being referred to more favorably in the media.
4basebio has higher earnings, but lower revenue than Avacta Group. 4basebio is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks.
4basebio has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, Avacta Group has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500.
Summary
4basebio and Avacta Group tied by winning 7 of the 14 factors compared between the two stocks.
Get Avacta Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avacta Group Competitors List
Related Companies and Tools
